Welcome to Markets Desk, here's what's moving the needle right now.
Pfizer and BioNTech have cleared a significant regulatory hurdle, with the FDA approving their updated COVID vaccine, COMIRNATY XFG, targeting the XFG variant for the two thousand twenty six to two thousand twenty seven season. The approval covers at-risk adults and keeps both companies positioned in a market that remains commercially meaningful despite pandemic fatigue.
Shifting to a smaller name drawing attention, Outlook Therapeutics is moving its stock higher after naming Kevin Lundquist as incoming Chief Financial Officer, effective September first, two thousand twenty six. The leadership transition sets up the biopharmaceutical firm ahead of its U.S. launch of LYTENAVA, a retinal disease treatment the company is betting its near-term commercial story on.
And on the infrastructure front, OpenAI CEO Sam Altman is acknowledging what critics have been saying loudly — Americans are deeply skeptical of data centers. Altman told Time magazine that public hostility is real and growing, an uncomfortable admission for a company planning to spend fifty billion dollars on compute this year, particularly as its own head of infrastructure has stepped down.
That's the tape. Markets Desk, signing off the floor.
